FUDANZHANGJIANG - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever as to the accuracy or completeness of the whole or any part of this announcement. assumes no liability for any loss arising from or arising from reliance on such content. Overseas regulatory announcement This announcement is made by Shanghai Fudan Zhangjiang Biopharmaceutical Co., Ltd. (the "Company") under the Hong Kong Stock Exchange Ltd. Securities Listing Rules 13.10(B). This is to set forth the "Relationships of Shanghai Fudan Zhangjiang Biopharmaceutical Co., Ltd." published by the company on the website of the Shanghai Stock Exchange. Announcement on the Re-appointment of the Accounting Firm" is for reference only. This document and its disclosure contents are prepared in accordance with Chinese laws and regulations. Prepared and published in accordance with relevant domestic regulatory requirements. By order of the board of directors Zhao Dajun Chairman As at the date of this announcement, the Board of Directors includes the following individuals: Mr. Zhao Dajun (Executive Director) Ms. Xue Yan (Executive Director) Mr. Shen Bo (Non-executive Director) Ms. Yu Xiaoyang (Non-executive Director) Mr. Wang Hongguang (Independent Non-executive Director) Mr. Lam Siu Wing (Independent Non-executive Director) Mr. Xu Peilong (Independent Non-executive Director) Ms. Qu Yanan (Employee Director) Shanghai, China March 30, 2026 *Identification only Securities code: 688505 Securities abbreviation: Fudan Zhangjiang Number: Lin 2026-009 Shanghai Fudan Zhangjiang Biopharmaceutical Co., Ltd. Announcement on Re-appointment of Accounting Firm The board of directors and all directors of the company guarantee that the contents of this announcement do not contain any false records, misleading statements or misleading statements. serious omissions, and shall bear legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law. Important content reminder:  The name of the accounting firm to be re-appointed in 2026: PricewaterhouseCoopers Zhongtian Accounting Firm (Specialized special general partnership) (hereinafter referred to as "PwC Zhongtian");  This proposal still needs to be submitted to Shanghai Fudan Zhangjiang Biopharmaceutical Co., Ltd. (hereinafter referred to as the "Company"). "Company" or "Fudan Zhangjiang") 2025 Annual Shareholders Meeting for review. 1. Basic information on the proposed re-appointment of the accounting firm (1) Institutional information 1. Basic information PricewaterhouseCoopers Zhongtian was formerly known as PricewaterhouseCoopers Dahua Certified Public Accountants LLP, which was established on March 28, 1993. Upon approval In June 2000, it was renamed PricewaterhouseCoopers Zhongtian Accounting Firm Co., Ltd.; as of December 24, 2012, Approved by Ministry of Finance Accounting Letter [2012] No. 52, it was transformed into PricewaterhouseCoopers Zhongtian Accounting Firm on January 18, 2013. (special general partnership). The registered address is No. 555, Haiyang West Road, Dongyu, China (Shanghai) Pilot Free Trade Zone Units 4501 and 4504 on the 45th floor of No. 588 Road. PricewaterhouseCoopers Zhongtian has an accounting firm practice certificate and is qualified to engage in auditing business for H-share companies. Quality. In addition, PwC Zhongtian is a member of the PwC International network and is also a member of the U.S. public companies Registered with the Accounting Oversight Board (USPCAOB) to engage in relevant auditing services. The chief partner of PwC Zhongtian is Li Dan. As of December 31, 2025, PwC Zhongtianhe The number of employees is 172, and the number of certified public accountants is more than 940, including those who have signed securities service industry certification since 2013. The number of certified public accountants producing financial audit reports is more than 200. The most recent accountant audited by PwC Zhongtian The total revenue for the year (2024) is RMB 6.319 billion, and the audit business revenue is RMB 5.770 billion. 1/4 yuan, and securities business income was RMB 2.536 billion. PwC Zhongtian’s number of listed company financial statement audit clients in 2024 (including A shares and B shares) is 29 companies, with a total financial statement audit fee of RMB 82.0881 million for listed companies. The main industries include manufacturing Manufacturing industry, transportation, warehousing and postal industry, wholesale and retail industry, leasing and business service industry, etc. 2. Investor protection capabilities In terms of investor protection capabilities, PwC Zhongtian has purchased occupational insurance in accordance with relevant laws and regulations. insurance, the cumulative compensation limit of occupational insurance and the occupational risk fund exceed RMB 200 million, and the occupational risk fund The accrual of funds or the purchase of occupational insurance comply with relevant regulations. In the past three years, PricewaterhouseCoopers Zhongtian has been involved in relevant civil cases due to its professional conduct. The situations in which civil liability is assumed in civil litigation are as follows: In relevant civil litigation cases, the effective judgment of the court determines that the general HuaCoopers Zhongtian shall bear 3% of the joint and several liability for investor losses within the scope of liability of listed companies, and has agreed to RMB 20,000. 3. Integrity record PwC Zhongtian and its employees have not been subject to any criminal penalties or industry penalties due to professional conduct in the past three years. Disciplinary actions by self-regulatory organizations such as associations. PwC Zhongtian was once criticized by the securities regulatory authorities for the same project. and industry authorities once each, and was subject to disciplinary sanctions once by the Shanghai and Shenzhen stock exchanges, three times Employees were subject to administrative penalties from securities regulatory agencies and industry authorities due to this project. Once and once each from the Shanghai and Shenzhen Stock Exchanges, eight employees were punished by industry supervisors for this project Administrative penalties from the department will be imposed once each. In addition, PwC Zhongtian was subject to warning letters issued by securities regulators. Supervision and management measures were taken four times, and self-regulatory measures were issued three times by the stock exchange with supervisory warnings. Nine practitioners Personnel were subject to one administrative penalty each by the industry authorities, and eight practitioners were punished by the securities regulatory agency administrative supervision measures once each, and six employees were subject to self-regulatory supervision measures by the stock exchange once each. (2) Project information 1. Basic information Project partner and signing CPA: Zhou Qinjun, practicing member of the Institute of Certified Public Accountants, 2008 Became a certified public accountant in 2005 and started auditing listed companies in 2005. From 2010 to 2015 and 2017 Since 2020 and 2024, he has provided audit services to the company. He has been working at PricewaterhouseCoopers since 2005. He has been practicing since then and has signed or reviewed the audit reports of 2 listed companies in the past 3 years. Project quality review partner: He Ting, a practicing member of the Institute of Certified Public Accountants, a registered accountant since 2007 Accountant, started practicing at PricewaterhouseCoopers Zhongtian in 2004, started auditing listed companies in 2004, 2024 2/4 He began to provide audit services to the company in 2008 and has signed or reviewed the audit reports of 6 listed companies in the past three years. Signing CPA: Sun Lini, a practicing member of the Institute of Certified Public Accountants, a member of the CPA since 2015 Accountant, started practicing at PricewaterhouseCoopers Zhongtian in 2009, started auditing listed companies in 2009, 2025 He began to provide audit services to the company in 2015 and has signed or reviewed the audit reports of 2 listed companies in the past three years. 2. Integrity record PwC Zhongtian plans to be hired as the company’s audit agency, project partner and signature registration in 2026 Accountant Mr. Zhou Qinjun, quality review partner Mr. He Ting and signing certified public accountant Ms. Sun Lini recently He has not been subject to any criminal punishment or administrative penalty for three years, and has not been subject to any action by the securities regulatory authority due to his professional conduct. We have implemented political supervision and management measures, and have not been subject to self-regulatory supervision by self-regulatory organizations such as stock exchanges and industry associations due to our professional behavior. management measures and disciplinary sanctions. 3. Independence Regarding PwC Zhongtian’s plan to be hired as the company’s auditor in 2026, PwC Zhongtian and the project partner Partner and signing certified public accountant Mr. Zhou Qinjun, quality review partner Mr. He Ting and signing certified public accountant Ms. Sun Lini has no circumstances that may affect her independence. 4. Audit fees The audit fees for the company's 2025 financial statements are RMB 3.8283 million, a decrease of 4% from 2024. The company's internal control audit fees for 2025 are the same as those for 2024, which is RMB 50 Ten thousand yuan. The audit service fees for 2026 are planned to be determined by both parties based on the audit workload and the principles of fairness and reasonableness. Determined, the specific amount will refer to the amount of audit fees in previous years and based on the 2026 audit project workload and general HuaCoopers Zhongtian negotiated and determined. 2. Procedures to be followed by the accounting firm to be re-appointed (1) Opinions of the Audit Committee of the Board of Directors The Audit Committee of the Board of Directors conducted a strict review of PwC Zhongtian’s qualifications. Post the following comments: PwC Zhongtian has the qualifications to practice relevant businesses and has strong professional capabilities and investor protection capabilities. He has extensive domestic and overseas auditing experience, is independent and has good integrity, and is able to win Responsible for the company's domestic and overseas audit-related work. Agree that the company plans to continue to hire PricewaterhouseCoopers Zhongtian as the company's audit agency in 2026 to provide audit services for the company. Planning related services. Agree to submit the proposal to the 15th meeting of the company's eighth board of directors for review. 3/4 (2) Review and voting by the board of directors The company held the 15th meeting of the eighth board of directors on March 30, 2026 to review and approve the "About the Continuation of Proposal to Appoint Domestic and Foreign Accounting Firms in 2026", agreeing that the company plans to continue to hire PricewaterhouseCoopers in 2026 Dao Zhongtian is the company's domestic and overseas financial report audit agency and domestic internal control audit agency for 2026. The appointment period One year, and the company's shareholders meeting is requested to authorize the company's board of directors and its authorized persons to negotiate with PricewaterhouseCoopers Zhongtian to determine Relevant audit fees and signing of relevant contracts and other matters. (3) The company’s renewal of the accounting firm needs to be submitted to the company’s 2025 annual shareholders’ meeting for review. And it will take effect from the date of review and approval by the company's shareholders' meeting. Announcement is hereby made. Shanghai Fudan Zhangjiang Biopharmaceutical Co., Ltd. board of directors March 31, 2026 4/4